SPONSOR
Guangdong Association of Clinical Trials
Total Trials
5
Recruiting
5
Phases
Phase 2
Conditions studied: ALK Positive Non-small Cell Lung CancerImmunotherapyLung CancerPatients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLCEGFR Mutation-negative and ALK Rearrangement-negativeEastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2No Prior Systemic Therapy Received for the Advanced or Metastatic DiseasePD-L1 Positive, as Determined by a Validated AssayNSCLC (Non-small Cell Lung Cancer)MRD
Guangdong Association of Clinical Trials is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including ALK Positive Non-small Cell Lung Cancer, Immunotherapy, Lung Cancer, Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Guangdong Association of Clinical Trials
How many clinical trials has Guangdong Association of Clinical Trials sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Guangdong Association of Clinical Trials, of which 5 are actively recruiting participants. These trials cover conditions including ALK Positive Non-small Cell Lung Cancer, Immunotherapy, Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Guangdong Association of Clinical Trials research focus on?
Guangdong Association of Clinical Trials clinical trials span ALK Positive Non-small Cell Lung Cancer, Immunotherapy, Lung Cancer, Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Guangdong Association of Clinical Trials clinical trial?
To participate in a Guangdong Association of Clinical Trials trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Guangdong Association of Clinical Trials trials with current recruitment status updated daily.
Clinical Trials by Guangdong Association of Clinical Trials
NCT06092086 Phase 2
Recruiting
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
ALK Positive Non-small Cell Lung Cancer
NCT04286841
Recruiting
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
Immunotherapy
NCT07696832
Recruiting
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC
NCT07120698 Phase 2
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NSCLC (Non-small Cell Lung Cancer)
NCT07198841 Phase 2
Recruiting
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Lung Cancer (Non-Small Cell)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology